Zofran ODT

DRUG2 trials

Sponsors

Par Pharmaceutical, Inc., Halozyme Therapeutics

Conditions

Healthy

Phase 1

Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions

CompletedNCT00659685

Par Pharmaceutical, Inc.Healthy

Start: 2003-11-30Updated: 2008-04-16

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

CompletedNCT01572012

Halozyme TherapeuticsHealthy

Start: 2012-02-29End: 2013-11-30Updated: 2014-01-24

Related Papers

Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.

2014-01-3113 citations